EQUASENS: results of the votes on the resolutions submitted to the ordinary annual shareholders’ meeting of 29 june 2023
Advertisement
Villers-lès-Nancy, 5 July 2023 – 6:00 p.m. (CET)
PRESS RELEASE
RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED
Advertisement
TO THE ORDINARY ANNUAL SHAREHOLDERS’ MEETING
OF 29 JUNE 2023
Number of shares comprising the share capital: 15,174,125
Number of shares with voting rights: 15,032,834
Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 13,046,120
That means a quorum of 86.78% of the 15,032,834 shares with voting rights: the Ordinary Annual General Meeting was able to deliberate.
The Ordinary Annual General Meeting was held on Thursday, 29 June 2023 at 5:30 p.m. at the Company’s headquarters and approved the separate parent company and consolidated financial statements for the 2022 financial year. The results of the votes on the resolutions proposed at this meeting by the Board of Directors were as follows:
| Resolutions |
Results of the votes
|
Approval of the annual financial statements |
Resolution adopted by:
|
Discharge of directors and discharge of the Statutory Auditors for the performance of their engagement |
Resolution adopted by:
|
|
Resolution adopted by:
|
Appropriation of earnings, setting the dividend |
Resolution adopted by:
|
Agreements and commitments governed by Articles L. 225-38 of the French Commercial Code |
Resolution adopted by (*):
|
Renewal of Ms. Anne LHOTE’s term of office as Director |
Resolution adopted by:
|
Renewal of Ms. Céline GRIS’s term of office as Independant Director |
Resolution adopted by:
|
Renewal of Ms. Émilie LECOMTE’s term of office as Director |
Resolution adopted by:
|
Appointment of a new Director |
Resolution adopted by:
|
Appointment of a new Statutory Auditor |
Resolution adopted by:
|
Approval of the information on the compensation of corporate officers paid in or granted for fiscal 2022 and mentioned in Article L. 22-10-9 of the French Commercial Code |
Resolution adopted by:
|
Approval of the components of compensation paid in 2022 to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors |
Resolution adopted by:
|
Approval of the components of compensation paid in 2022 to Mr. Dominique PAUTRAT, Chief Executive Officer |
Resolution adopted by:
|
Approval of the components of compensation paid in 2022 to Mr. Denis SUPPLISSON, Deputy Chief Executive Officer and then Chief Executive Officer |
Resolution adopted by:
|
Approval of the components of compensation paid in 2022 to Mr. Grégoire DE ROTALIER, Deputy CEO |
Resolution adopted by:
|
Approval of the compensation policy for the Chairman of the Board of Directors for 2023 |
Resolution adopted by:
|
Approval of the compensation policy for Mr. Denis SUPPLISSON, Chief Executive Officer, for 2023 |
Resolution adopted by:
|
Approval of the compensation policy for Mr. Grégoire de ROTALIER, Deputy Chief Executive Officer, for 2023 |
Resolution adopted by:
|
Approval of the compensation policy for Directors |
Resolution adopted by:
|
Setting total annual compensation for Directors for 2023 |
Resolution adopted by:
|
Authorisation by the Company to repurchase its own shares |
Resolution adopted by:
|
Powers for formalities |
Resolution adopted by:
|
(*) After deduction of excluded voting rights
Financial Calendar:
- Publication of H1 2023 Revenue: 3 August 2023, after French market closure.
About Group Equasens
Founded more than 35 years ago, Equasens Group, which now has more than 1,200 employees in Europe, is the leading publisher of software solutions for the healthcare industry in terms of the diversity of its business applications and market share.
Equasens Group’s specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as financing and training adapted to their specific needs.
And reflecting the spirit of its tagline ” technology for a more human experience“, the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient healthcare system.
Listed on Euronext Paris™ – Compartment A
Indexes: MSCI GLOBAL SMALL CAP – GAÏA Index 2020 – CAC® SMALL and CAC® All-Tradable
Included in the Euronext Tech Leaders segment and the European Rising Tech label
Eligible for the Deferred Settlement Service (“Service à Règlement Différé” – SRD) and equity savings accounts invested in small and mid caps (PEA-PME)
ISIN: FR 0012882389 – Ticker Code: EQS
Get all the news about the Equasens Group www.equasens.com and on LinkedIn
CONTACTS
Analyst and Investor Relations:
Chief Administrative and Financial Officer: Frédérique SCHMIDT
Tel. +33 (0)3 83 15 90 67 – [email protected]
Media Relations:
FIN’EXTENSO – Isabelle APRILE
Tel. +33 (0)6 17 38 61 78 – [email protected]
Attachment
- EQUASENS_PRESSRELEASE_20230705_RESULTS OF THE VOTES_en_US
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.